Cognito Therapeutics

💭 Cognitive Health· 📍 Cambridge, MA, USA

Overview

Cognito Therapeutics is developing non-invasive sensory stimulation therapies using 40Hz gamma frequency light and sound to target the neurological mechanisms underlying Alzheimer's disease. Their OVERTURE Phase 3 clinical trial is evaluating the Cognito Therapy System for slowing cognitive and functional decline in mild-to-moderate Alzheimer's patients.

More in Cognitive Health

Myelin Health

Boston, MA

Axon Park

Toronto, Ontario, Canada

Cortical.io

Vienna, Austria

Qualia Life Sciences

BrainCare

Oxford, UK

Cogstate

Melbourne, Australia

Latest industry news

FDA Grants De Novo Approval to Modius Spero, Clearing First Neuromodulation Device for PTSD

2026-09-03 · Policy

Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%

2026-09-02 · Industry

Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream

2026-09-01 · Industry

FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface

2026-08-31 · Policy

Company details

Is this your company?

Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.

Claim & upgrade listing

Advertise

Reach neurotech professionals

Newsletter sponsorships, featured listings, and sponsored articles.

View packages →